Cocrystal Pharma, Inc. (COCP): who owns it and who trades it
As of Nov 16, 2026, COCP insiders reported 11 purchases worth $301K in the last 12 months. The largest buyer was Phillip Md Et Al Frost (Director), with $301K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Cocrystal Pharma
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, COCP insiders reported $301K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | Phillip Md Et Al Frost | Director | Purchase | 10,000 | $0.98 | $9.8K | Form 4 |
| Aug 3, 2026 | Phillip Md Et Al Frost | Director | Purchase | 75,000 | $0.94 | $70.5K | Form 4 |
| Feb 24, 2026 | Phillip Md Et Al Frost | Director | Purchase | 20,000 | $1.00 | $20K | Form 4 |
| Feb 6, 2026 | Phillip Md Et Al Frost | Director | Purchase | 50,000 | $0.95 | $47.5K | Form 4 |
| Dec 31, 2025 | Phillip Md Et Al Frost | Director | Purchase | 50,000 | $0.95 | $47.5K | Form 4 |
| Dec 30, 2025 | Phillip Md Et Al Frost | Director | Purchase | 20,000 | $0.97 | $19.4K | Form 4 |
| Dec 26, 2025 | Phillip Md Et Al Frost | Director | Purchase | 40,000 | $0.97 | $38.8K | Form 4 |
| Dec 24, 2025 | Phillip Md Et Al Frost | Director | Purchase | 25,000 | $0.97 | $24.2K | Form 4 |
| Nov 26, 2025 | Phillip Md Et Al Frost | Director | Purchase | 2,500 | $0.99 | $2.5K | Form 4 |
| Nov 26, 2025 | Phillip Md Et Al Frost | Director | Purchase | 1,500 | $1.00 | $1.5K | Form 4 |
| Nov 25, 2025 | Phillip Md Et Al Frost | Director | Purchase | 20,000 | $0.94 | $18.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Phillip Md Et Al Frost | Director, 10% owner | $301K | – | Aug 5, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
COCP short interest
Low short interest. 0.9% of COCP shares are sold short: about 1 share in 106. Over the last 12 reports the number of shares short went down 6%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 181,361 COCP shares were sold short, 0.9% of the shares outstanding, up 1.2% from the report before. At the average daily volume of 36,841 shares, buying them all back would take about 4.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 181,361 | 0.94% | +1% | 36,841 | 4.9 |
| Oct 15, 2026 | 179,193 | 0.93% | +2% | 36,626 | 4.9 |
| Sep 30, 2026 | 175,246 | 0.91% | -46% | 54,337 | 3.2 |
| Sep 15, 2026 | 322,748 | 1.68% | +0% | 50,239 | 6.4 |
| Aug 31, 2026 | 322,544 | 1.67% | +5% | 61,538 | 5.2 |
| Aug 14, 2026 | 307,605 | 1.60% | -21% | 109,449 | 2.8 |
| Jul 31, 2026 | 388,004 | 2.81% | -2% | 27,416 | 14.2 |
| Jul 15, 2026 | 395,023 | 2.87% | -2% | 26,591 | 14.9 |
| Jun 30, 2026 | 404,505 | 2.93% | -1% | 90,459 | 4.5 |
| Jun 15, 2026 | 410,154 | 2.98% | +186% | 108,694 | 3.8 |
| May 29, 2026 | 143,168 | 1.04% | -26% | 130,765 | 1.1 |
| May 15, 2026 | 192,682 | 1.40% | -67% | 138,014 | 1.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Cocrystal Pharma company events
Cocrystal Pharma filed 17 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Sep 9, 2026.
- Sep 9, 2026AnnouncementShared information with investors. Filing
- Aug 18, 2026LeadershipThe Board of Directors of Cocrystal Pharma, Inc. appointed Carol L. Brosgart as a director of the Company, effective immediately. Filing
- Aug 17, 2026AnnouncementShared information with investors. Filing
- Aug 3, 2026AgreementEntry into Material Definitive Agreement. Filing
- Jul 17, 2026VoteReported shareholder vote results. Filing
- Jun 9, 2026LeadershipThe Board of Directors of Cocrystal Pharma, Inc. appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately, pursuant to the terms of an employment offer letter. Filing
- Jun 3, 2026AnnouncementShared information with investors. Filing
- May 26, 2026AnnouncementShared information with investors. Filing
- Apr 30, 2026AnnouncementShared information with investors. Filing
- Apr 2, 2026AnnouncementShared information with investors. Filing
- Mar 31, 2026ResultsReleased financial results. Filing
- Mar 13, 2026LeadershipCocrystal Pharma, Inc. sadly learned on March 10, 2026 that Dr. Anthony Japour, a member of the Company’s board of directors, passed away. Filing
- Mar 9, 2026AnnouncementShared information with investors. Filing
- Feb 19, 2026AnnouncementShared information with investors. Filing
- Jan 15, 2026LeadershipThe Compensation Committee of the Board of Directors of Cocrystal Pharma, Inc. approved the grant of non-qualified stock options to the Company’s directors, executive officers and a certain consultant. Filing
- Dec 18, 2025AnnouncementShared information with investors. Filing
- Dec 1, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Cocrystal Pharma financials
Famous investors that hold COCP
2 of the 50 well-known investors we track reported holding COCP in their latest 13F filing. The largest position is Jim Simons's, worth $201K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 174,998 | $201K | 0.0% | -3% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 42,669 | $49.1K | 0.0% | -5% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named COCP in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 6, 2026 | OPKO HEALTH, INC. | 13D/A | 29.6% |
| Nov 6, 2026 | OPKO HEALTH, INC. | 13D/A | 29.6% |
Questions about Cocrystal Pharma, Inc. (COCP) stock
Are COCP insiders buying or selling?
In the last 12 months, COCP insiders reported 11 open-market purchases worth $301K and no sales. The latest trade was on Aug 5, 2026. See every trade.
What is the short interest in COCP?
As of Oct 30, 2026, 181,361 COCP shares were sold short, 0.9% of the shares outstanding, up 1.2% from the report before. At the average daily volume of 36,841 shares, buying them all back would take about 4.9 trading days (days to cover). See the history.
Which famous investors hold COCP?
2 of the 50 well-known investors we track reported COCP in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $201K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.